State Street’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$73M Sell
8,970,518
-553,128
-6% -$5.01M ﹤0.01% 1552
2025
Q4
$64M Buy
9,523,646
+2,326,927
+32% +$17.5M ﹤0.01% 1611
2025
Q3
$62.4M Buy
7,196,719
+372,468
+5% +$2.9M ﹤0.01% 1621
2025
Q2
$43M Sell
6,824,251
-214,907
-3% -$1.42M ﹤0.01% 1755
2025
Q1
$45.1M Sell
7,039,158
-662,208
-9% -$5.47M ﹤0.01% 1699
2024
Q4
$61.9M Buy
7,701,366
+13,415
+0.2% +$129K ﹤0.01% 1612
2024
Q3
$97.1M Buy
7,687,951
+1,621,772
+27% +$20.9M ﹤0.01% 1342
2024
Q2
$76.8M Sell
6,066,179
-10,840,391
-64% -$109M ﹤0.01% 1434
2024
Q1
$80.8M Buy
16,906,570
+130,695
+0.8% +$606K ﹤0.01% 1442
2023
Q4
$80.5M Buy
16,775,875
+6,601,258
+65% +$40.4M ﹤0.01% 1435
2023
Q3
$73.7M Sell
10,174,617
-1,504,811
-13% -$12M ﹤0.01% 1382
2023
Q2
$86.8M Buy
11,679,428
+576,803
+5% +$4.54M ﹤0.01% 1320
2023
Q1
$76.9M Buy
11,102,625
+5,026,107
+83% +$46.2M ﹤0.01% 1362
2022
Q4
$62.5M Buy
6,076,518
+2,421,090
+66% +$42.7M ﹤0.01% 1477
2022
Q3
$66.5M Buy
3,655,428
+688,564
+23% +$29.8M ﹤0.01% 1399
2022
Q2
$153M Buy
2,966,864
+471,322
+19% +$24.4M 0.01% 888
2022
Q1
$184M Buy
2,495,542
+596,322
+31% +$53.2M 0.01% 888
2021
Q4
$272M Buy
1,899,220
+152,593
+9% +$26.2M 0.01% 721
2021
Q3
$362M Buy
1,746,627
+53,237
+3% +$11.7M 0.02% 607
2021
Q2
$360M Buy
1,693,390
+251,437
+17% +$46.1M 0.02% 631
2021
Q1
$261M Sell
1,441,953
-284,229
-16% -$56.6M 0.02% 695
2020
Q4
$192M Buy
1,726,182
+17,323
+1% +$1.84M 0.01% 765
2020
Q3
$185M Sell
1,708,859
-604,488
-26% -$73.6M 0.01% 705
2020
Q2
$193M Buy
2,313,347
+1,733,715
+299% +$66.3M 0.01% 669
2020
Q1
$7.87M Buy
579,632
+152,556
+36% +$1.29M ﹤0.01% 2407
2019
Q4
$1.7M Buy
427,076
+2,887
+0.7% +$12.5K ﹤0.01% 3298
2019
Q3
$2.13M Buy
424,189
+14,066
+3% +$77K ﹤0.01% 3195
2019
Q2
$2.4M Buy
410,123
+19,950
+5% +$157K ﹤0.01% 3168
2019
Q1
$4.3M Sell
390,173
-345,807
-47% -$10.9M ﹤0.01% 2814
2018
Q4
$27.1M Sell
735,980
-132,911
-15% -$5.15M ﹤0.01% 1780
2018
Q3
$32.7M Sell
868,891
-296,494
-25% -$8.35M ﹤0.01% 1832
2018
Q2
$31.2M Sell
1,165,385
-96,194
-8% -$3.25M ﹤0.01% 1826
2018
Q1
$53M Buy
1,261,579
+656,084
+108% +$26.4M ﹤0.01% 1389
2017
Q4
$15M Buy
605,495
+341,366
+129% +$8.33M ﹤0.01% 2244
2017
Q3
$6.02M Sell
264,129
-278
-0.1% -$6.22K ﹤0.01% 2700
2017
Q2
$6.08M Sell
264,407
-390,737
-60% -$7.67M ﹤0.01% 2639
2017
Q1
$16.8M Sell
655,144
-343,408
-34% -$9.44M ﹤0.01% 2070
2016
Q4
$25.2M Buy
998,552
+497,374
+99% +$14.5M ﹤0.01% 1732
2016
Q3
$20.8M Buy
501,178
+50,446
+11% +$6.51M ﹤0.01% 1745
2016
Q2
$65.5M Sell
450,732
-165,310
-27% -$18.9M 0.01% 1048
2016
Q1
$63.6M Buy
616,042
+176,386
+40% +$18.9M 0.01% 1064
2015
Q4
$73.8M Buy
439,656
+81,013
+23% +$12.5M 0.01% 968
2015
Q3
$50.7M Buy
358,643
+2,103
+0.6% +$472K 0.01% 1162
2015
Q2
$79.4M Buy
356,540
+47,046
+15% +$8.27M 0.01% 979
2015
Q1
$51.2M Sell
309,494
-21,357
-6% -$3.47M 0.01% 1225
2014
Q4
$39.2M Sell
330,851
-16,775
-5% -$1.75M ﹤0.01% 1345
2014
Q3
$29M Buy
347,626
+39,279
+13% +$3.55M ﹤0.01% 1469
2014
Q2
$28.5M Sell
308,347
-11,247
-4% -$988K ﹤0.01% 1566
2014
Q1
$29M Sell
319,594
-19,980
-6% -$2.23M ﹤0.01% 1509
2013
Q4
$34.8M Buy
339,574
+233,075
+219% +$16.5M ﹤0.01% 1397
2013
Q3
$6.74M Buy
106,499
+5,029
+5% +$283K ﹤0.01% 2354
2013
Q2
$4.16M Buy
+101,470
New +$4.4M ﹤0.01% 2570

Other funds holding NVAX

State Street's NVAX Position: Q1 2026 in Review

State Street reduced its Novavax (NVAX) stake by 5.8% in Q1 2026, selling an estimated $5.01M and leaving 8,970,518 shares worth $73M. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

State Street first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $362M in Q3 2021. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • State Street held 8,970,518 shares of Novavax worth $73M as of Q1 2026.
  • State Street sold 553,128 Novavax shares in Q1 2026, an estimated $5.01M.
  • Novavax made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1552 holding.
  • State Street first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
  • State Street's Novavax position peaked at $362M in Q3 2021.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.